摘要
本文阐述了急性脑梗死的药物治疗进展。重点介绍了脑梗死的治疗关键是尽早挽救"缺血半暗带"的超早期溶栓治疗,即发病6h内的"治疗窗",目前国内常用的溶栓药物为尿激酶;早期的治疗包括降纤(代表药物为东菱克栓酶),抑制血小板聚集以奥扎格雷钠疗效优且安全可靠,纤溶酶是新一代溶栓抗凝药物;进展型脑卒中的治疗以抗凝、抑制血栓形成的治疗尤为重要,临床常用降纤酶与低分子肝素联合治疗。本文还就各种代表药物的作用机制进行了探讨。
This paper elaborates the progress of medication on acute cerebral infarction.It emphasizes that the key to treat cerebral infarction is the ultra-early thrombolytic therapy which can save ischemic penumbra as early as possible,that is,the ＂therapeutic window＂ within 6h from the attack.At present,the common thrombolytic drug used in our country is urokinase;early treatments include defibringen（the representative drug is batroxobin）,and the sodium ozagrel has a good therapeutic effect and is safe and reliable in the inhibition of platelet aggregation,and fibrinolysin is a new kind of thrombolytic and anticoagulative drug;the treatment of progressive stroke especially emphasizes on anticoagulation and inhibition of thrombus,and defibrase is often used in combination with low molecular heparin in clinical treatment.This paper also probes into the mechanism of various representative drugs.
出处
《保健医学研究与实践》
2012年第2期75-78,共4页
Health Medicine Research and Practice
关键词
急性脑梗死
药物治疗
缺血半暗带
治疗窗
Acute cerebral infarction
Medication
Ischemic penumbra
Therapeutic window
